Explanipedia

A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases Open

Lucy Boyce Kennedy, Amanda E.D. Van Swearingen, Marissa R. Lee, Layne W. Rogers, Alexander B. Sibley , et al. · 2025

Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases Open

Laura Alder, Gloria Broadwater, Michelle Green, Amanda E.D. Van Swearingen, Eric Lipp , et al. · 2024

Background Although serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in 3 groups: Isolated BrMs with st…

EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA Open

Tamrin Chowdhury, Kevin C. Johnson, Emre Kocakavuk, Chaewon Heo, Gordon Y. Ye , et al. · 2023

Oligodendroglioma is characterized by oligodendrocyte-like histology, mutation in the IDH genes, along with codeletion of chromosome arms 1p and 19q. Treatment for oligodendrogliomas combines surgery, followed by observation, and chemother…

CTIM-09. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG) Open

Annick Desjardins, Vidya Chandramohan, Daniel Landi, Katherine B. Peters, Margaret Johnson , et al. · 2023

BACKGROUND D2C7-IT is a dual-specific immunotoxin. Recombinant antibody fragments bind the wild-type epidermal growth factor receptor (EGFRwt) and its mutant EGFR variant III (EGFRvIII), triggering internalization and intracellular deliver…

QLTI-05. COST TOXICITY OF ORAL CHEMOTHERAPY IN PRIMARY BRAIN TUMOR PATIENTS Open

Mallika Patel, Mary Lou Affronti, Evan Buckley, James E. Herndon, Eric Lipp , et al. · 2023

BACKGROUND Costs associated with cancer treatments in the United States continue to rise as new therapies are approved. Financial toxicity describes both the quantifiable costs associated with cancer as well as the distressful effects rela…

IMMU-11. <i>NLRP3+</i> TUMOR-ASSOCIATED MYELOID CELLS ARE ENRICHED IN ASTROCYTIC GLIOMAS AND REPRESENT A THERAPEUTIC VULNERABILITY Open

Vidya Chandramohan, Kevin Stevenson, Yen‐Rei Yu, Zachary J. Reitman, Yiping He , et al. · 2023

BACKGROUND Tumor-associated myeloid cells (TAMs) are known drivers of immunosuppression and glioma progression. Hence novel approaches for repolarizing TAMs from a protumorigenic to an antitumorigenic phenotype is an active area of investi…

TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET) Open

Amanda E.D. Van Swearingen, Sarah Sammons, Laura Noteware, Nusayba A. Bagegni, Kelly Moulton , et al. · 2023

Despite trastuzumab-based therapy, up to half of patients with HER2+ metastatic breast cancer (MBC) will develop brain metastases (BrM). First-line therapy for HER2+ MBC, taxane/trastuzumab/pertuzumab (TP), demonstrates poor brain permeabi…

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial Open

Eric M. Thompson, Daniel Landi, Michael C. Brown, Henry S. Friedman, Roger E. McLendon , et al. · 2023

The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice Open

Alex Broom, Leah Williams Veazey, Katherine Kenny, Imogen Harper, Michelle Peterie , et al. · 2023

For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment for) cancer, pandem…

Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy Open

Kirsten A. White, Kate Connor, Maxime Meylan, Antoine Bougoüin, Manuela Salvucci , et al. · 2022

Determining venous thromboembolism risk in patients with adult-type diffuse glioma Open

Kirsten B. Burdett, Dusten Unruh, Michael Drumm, Alicia Steffens, Jonathan B. Lamano , et al. · 2022

Venous thromboembolism (VTE) is a life-threating condition that is common in patients with adult-type diffuse gliomas, yet thromboprophylaxis is controversial because of possible intracerebral hemorrhage. Effective VTE prediction models ex…

PATH-11. THE LONGITUDINAL EVOLUTIONARY TRAJECTORY OF OLIGODENDROGLIOMA IS DRIVEN BY TREATMENT-ASSOCIATED GENETIC ALTERATIONS Open

Frederick S. Varn, Gordon Y. Ye, Padmaja L. Ghospurkar, Taylor Wade, Mustafa Khasraw , et al. · 2022

Oligodendroglioma is a subtype of diffuse glioma defined by a mutation in the isocitrate dehydrogenase (IDH) genes and a co-deletion of chromosome arms 1p and 19q. These tumors primarily occur in adult patients in their third and fourth de…

TMIC-10. IDENTIFICATION, VALIDATION AND BIOLOGICAL CHARACTERIZATION OF NOVEL GLIOBLASTOMA TUMOUR MICROENVIRONMENT SUBTYPES: IMPLICATIONS FOR PRECISION IMMUNOTHERAPY Open

Kieron White, Kate Connor, Maxime Meylan, Antoine Bougoüin, Manuela Salvucci , et al. · 2022

New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts to subtype patients based on molecular profiles, have failed to direct treatment strategies. We hypothesized that interrogation of the…

QOL-08. PHASE II RANDOMIZED STUDY TO EVALUATE EFFICACY AND SATISFACTION OF ROLAPITANT PLUS ONDANSETRON VS. ONDANSETRON MONOTHERAPY IN PREVENTING NAUSEA/VOMITING FOR GLIOMAS RECEIVING RADIATION/TEMOZOLOMIDE Open

Mary Lou Affronti, Mallika Patel, Erin Severance, Charles Loughlin, Claire Bradbury , et al. · 2022

BACKGROUND Nausea and vomiting remain the most feared cancer treatment-related side effects. Trials establishing antiemetic guidelines exclude malignant glioma (MG) patients. In MG patients receiving radiation with concurrent temozolomide,…

CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS) Open

Annick Desjardins, Vidya Chandramohan, Daniel Landi, Katherine B. Peters, Margaret Johnson , et al. · 2022

BACKGROUND D2C7-IT, a novel immunotoxin-based cytotoxic therapy, targets epidermal growth factor receptor (EGFR) and mutant EGFR variant III. In preclinical studies, D2C7-IT kills tumor cells and prolongs survival, but is unable to generat…

QOL-06. PREDICTING VENOUS THROMBOEMBOLISM IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMAS Open

Kirsten B. Burdett, Dusten Unruh, Michael Drumm, Jonathan B. Lamano, Margaret Schwartz , et al. · 2022

Venous thromboembolism (VTE) is a common paraneoplastic complication in patients with adult-type diffuse gliomas. VTE greatly diminishes quality-of-life, and can even be life-threatening. While effective VTE prediction models exist for oth…

PATH-22. CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA Open

Madison L Shoaf, Frances Chow, Joanne Xiu, Michael Glantz, Sonikpreet Aulakh , et al. · 2022

INTRODUCTION Leptomeningeal disease (LMD) is a challenging complication of high grade glioma (HGG) and critical questions remain unanswered regarding clinicopathologic risk factors, molecular associations, and optimal treatment. METHODS Pa…

SPCR-03 NEUROCOGNITIVE OUTCOMES FROM PHASE 1 TRIAL OF BMX-001 IN COMBINATION WITH CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA PATIENTS Open

Katherine B. Peters, John P. Kirkpatrick, Ines Batinić‐Haberle, Mary Lou Affronti, Sarah Woodring , et al. · 2022

INTRODUCTION Neurocognitive dysfunction can result from radiation therapy which is the mainstay of treatment for high-grade glioma, particularly glioblastoma. Preclinical observations found that BMX-001, a novel metalloporphyrin, acts as a…

Patterns of care in adult histone mutant gliomas: Results of an international survey Open

Alexander Yuile, Mustafa Khasraw, Justin Low, Kyle M. Walsh, Eric Lipp , et al. · 2022

Background Histone mutant gliomas (HMG) with histone H3 K27 and G34 mutations are recognized as biologically discrete entities with distinct anatomical locations, younger age at presentation (in comparison to the most common high-grade gli…

Transcriptomic analysis reveals novel tumour microenvironment subtypes in IDH wildtype glioblastoma Open

Kieron White, Kate Connor, Maxime Meylan, Antoine Bougoin, Manuela Salvucci , et al. · 2022

QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS Open

Katherine B. Peters, Mary Lou Affronti, Jung-Young Kim, Mallika Patel, Margaret Johnson , et al. · 2021

Glioblastoma (GBM) patients can use tumor-treating fields (TTFs) with adjuvant temozolomide (TMZ) to treat their disease. TTFs involve wearing transfixed transducers to the shaved scalp, and the transducers are wired to a battery pack that…

BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM Open

Michael C. Brown, Gao Zhang, Kevin Stevenson, Xiang Lin, Yeqing Chen , et al. · 2021

BACKGROUND PVSRIPO is a live-attenuated recombinant rhino:poliovirus that mediates antitumor efficacy by engaging antitumor immunity. A subset (~20%) of patients with recurrent GBM (rGBM) survive >24 months after therapy. We previously …

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE Open

Margaret Johnson, Mustafa Khasraw, Jung-Young Kim, Nicole Cort, James E. Herndon , et al. · 2021

INTRODUCTION There is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, early referral to PC is not yet a reality for patients diagnosed with a primary brain tumor. We hypothesize that la…

Availability and role of clinical pharmacists in ambulatory neuro-oncology Open

Mallika Patel, Eric Lipp, Elizabeth Miller, Patrick Healy, James E. Herndon , et al. · 2021

Background Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist …

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis Open

Jennifer Kang, Christa B. Swisher, Evan Buckley, James E. Herndon, Eric Lipp , et al. · 2021

Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to a…

OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM) Open

Lucy Boyce Kennedy, Amanda E.D. Van Swearingen, Jeff Sheng, Dadong Zhang, Xiaodi Qin , et al. · 2021

Background MBM have a unique molecular profile compared to ECM. Methods We analyzed a previously published dataset from MD Anderson Cancer Center, including RNA-seq on surgically resected, FFPE MBM and ECM from the same patients. STAR pipe…

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS Open

Emily Hanzlik, Bridget Archambault, Mays Dairi, Kristin Schroeder, Mallika Patel , et al. · 2021

Circumscribed low-grade gliomas comprise roughly one-third of pediatric CNS tumors. Most of these tumors are caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Drugs targeting the MAPK pathway are effect…

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL Open

Eric M. Thompson, Daniel Landi, Gerald E. Archer, Eric Lipp, Ashley A. Walter , et al. · 2021

Introduction The cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not in healthy brain. The objective of this Phase I trial (NCT03299309) was to assess the safety and feasibility of…

Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial Open

Katherine B. Peters, Mary Lou Affronti, Sarah Woodring, Eric Lipp, Patrick Healy , et al. · 2021

Purpose: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for …

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis Open

Jessica W. Lee, John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric Lipp , et al. · 2021

Objectives Standard 6-week and hypofractionated 3-week courses of adjuvant radiation therapy (RT) are both options for older patients with glioblastoma (GBM), but deciding the optimal regimen can be challenging. This analysis explores clin…

Eric Lipp YOU? Author Swipe